Daily Archives: August 31, 2020
Perspective: COVID-19 vaccine trials should seek worthwhile efficacy
31 Aug, 2020 | 01:45h | UTCCOVID-19 vaccine trials should seek worthwhile efficacy – The Lancet
Commentary: Covid vaccine rush could make pandemic worse, say scientists – The Guardian
Commentary on Twitter
"Although efficacy far greater than 50% would be better, efficacy of about 50% would represent substantial progress"
Philip Krause et al for the @WHO Solidarity Vaccines Trial Expert Group on why #COVID19 vaccine trials should seek worthwhile efficacy https://t.co/2VWas8YU7L pic.twitter.com/RjbeZkeAE0
— The Lancet (@TheLancet) August 28, 2020
Study: Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2
31 Aug, 2020 | 01:47h | UTCRelated study: Salivary Detection of COVID-19 – Annals of Internal Medicine
Commentary on Twitter
Just published @NEJM
Strong support for saliva as an alternative to nasopharyngeal swab samples to detect #SARSCoV2
by @awyllie13 @YaleSPH and team @YaleMed https://t.co/waF5ODmiV8 pic.twitter.com/zw1D2JqW0y— Eric Topol (@EricTopol) August 28, 2020
Children might play a bigger role in COVID transmission than first thought. Schools must prepare
31 Aug, 2020 | 01:41h | UTC
A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU
31 Aug, 2020 | 01:44h | UTC
#ESCCongress – [Abstract Only] Randomized trial: Cardiovascular and renal outcomes with Empagliflozin in heart failure
31 Aug, 2020 | 01:38h | UTCCommentaries: EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF – TCTMD AND EMPEROR-Reduced meets primary endpoint in heart failure with reduced ejection fraction – European Society of Cardiology AND Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction – EMPEROR-Reduced – American College of Cardiology
Related study: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine
Commentary on Twitter
Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress
— NEJM (@NEJM) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: Early rhythm-control therapy in patients with atrial fibrillation
31 Aug, 2020 | 01:39h | UTCEarly Rhythm-Control Therapy in Patients with Atrial Fibrillation – New England Journal of Medicine
Commentaries: Early rhythm control therapy improves outcomes in patients with atrial fibrillation – European Society of Cardiology AND Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4 – TCTMD AND Early Treatment of Atrial Fibrillation for Stroke Prevention Trial – EAST-AFNET 4 – American College of Cardiology AND EAST-AFNET 4: Is Early Rhythm-Control Therapy Associated With Lower Risk of CV Outcomes in Early AFIB Patients? – American College of Cardiology
Commentary on Twitter
Original Article: Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST–AFNET 4 Trial) #ESCCongress
— NEJM (@NEJM) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: aspirin with or without clopidogrel after transcatheter aortic-valve implantation
31 Aug, 2020 | 01:33h | UTCCommentaries: Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic-Valve Implantation – POPular TAVI (antiplatelet therapy) – American College of Cardiology AND Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI – TCTMD
Commentary on Twitter
#ESCCongress #popular_TAVI
Aspirin vs Asp+Clop following #TAVR Aspirin alone:
➡️decrease in bleeding by 40%
➡️No increase in ischemic events
➡️ RRR 26% for net benefit@aayshacader @AnastasiaSMihai @mirvatalasnag @sbrugaletta @Ortega_Paz @willsuh76 @SVRaoMD @DrAsifQasim @iamritu pic.twitter.com/CvUdYgw5mG— Mamas Mamas (@mmamas1973) August 30, 2020
#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
31 Aug, 2020 | 01:36h | UTC
#ESCCongress – Initial invasive versus conservative management of stable ischemic heart disease patients with a history of heart failure or left ventricular dysfunction: Insights from the ISCHEMIA Trial
31 Aug, 2020 | 01:30h | UTC
Commentary on Twitter
ISCHEMIA Trial: In patients w/ischemia & CHF (LVEF 35-45%), an early invasive strategy might improve event-free survival #CircESC20 #ESCCongress #AHAJournals @RenatoDLopes1 @DCRINews @DukeHeartCenter @AHAScience https://t.co/G5FDD7ipL9 pic.twitter.com/joYIxGx544
— Circulation (@CircAHA) August 29, 2020
#ESCCongress – [Abstract Only] Randomized trial: Low-dose edoxaban in very elderly patients with atrial fibrillation
31 Aug, 2020 | 01:32h | UTCCommentaries: Edoxaban Low-Dose for Elder Care Atrial Fibrillation – ELDERCARE-AF – American College of Cardiology AND ELDERCARE-AF: Edoxaban Superior to Placebo in Preventing Stroke, Systemic Embolism in Elderly Japanese AFib Patients – American College of Cardiology
Commentary on Twitter
Elderly patients with AF who were not candidates for standard doses of oral anticoagulants because of a high risk of bleeding were assigned to receive 15 mg of edoxaban or placebo once daily. Edoxaban was superior to placebo in preventing stroke or systemic embolism. #ESCCongress
— NEJM (@NEJM) August 30, 2020
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
31 Aug, 2020 | 01:26h | UTCCommentaries: Colchicine to Improve Cardiovascular Outcomes in ACS Patients – COPS – Circulation
Commentary on Twitter
Colchicine in Patients with Acute Coronary Syndrome: The Australian COPS RCT vs COLCOT RCT #ESCCongress ? seemingly opposite results, dose start time patients? @almucastro01 @ValleAlfonso @JoseJuanatey @Dr_Manito @secardiologia @varrarte @sociedadSEEN ??https://t.co/uagW2HRGPt pic.twitter.com/SQoVsbzG0m
— Oscar Moreno # (@moreno_perez_o) August 30, 2020
#ESCCongress – Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
31 Aug, 2020 | 01:23h | UTCCommentary: Colchicine Cardiovascular Outcomes Trial – COLCOT – American College of Cardiology
Commentary on Twitter
#ESCCongress #COLCOT Study looking at TTI colchicine to assess if timing impacted outcomes
❤️ACS treatment with colchicine ? placebo: 23%⤵️ in events
❤️Randomized w/in 30days postMI
?TTI (Time to Treat Initiation) 0-3d ? 4-7d ? 8-30d
?0-3 days had better outcomes pic.twitter.com/iQAkts1BG9— Dr. Martha Gulati “Masks are the New Black” (@DrMarthaGulati) August 30, 2020
#ESCCongress – [Abstract Only] Randomized trial: Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy
31 Aug, 2020 | 01:21h | UTCCommentary: EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class – TCTMD
Commentary on Twitter
Latebreaking now at #ESCCongress—Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial https://t.co/JcJnGI0VVt pic.twitter.com/Xmf98Bcoir
— The Lancet (@TheLancet) August 29, 2020
#ESCCongress – 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
31 Aug, 2020 | 01:20h | UTCNews Release: How to treat the most common heart attacks – European Society of Cardiology
Commentary: 2020 ESC NSTE-ACS Guidelines: Key Points – American College of Cardiology
Commentary on Twitter
ESC 2020 Guidelines for non-ST elevation acute coronary syndrome just released https://t.co/dKIngRO59K#ESCCongress #ESCGuidelines #cardiotwitter #MedTwitter pic.twitter.com/ihcnxcCzBw
— European Society of Cardiology (@escardio) August 29, 2020
#ESCCongress – 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation
31 Aug, 2020 | 01:18h | UTCNews Release: Heart rhythm disorders are best managed when patients are listened to – European Society of Cardiology
Commentary on Twitter
2020 ESC Guidelines for diagnosis & management of atrial fibrillation https://t.co/SSuQAr13TO#ESCCongress @escardio @ESC_Journals @AChoiHeart @purviparwani @DrMarthaGulati @ErinMichos @DrPascalMeier pic.twitter.com/5cLRSJbldp
— Open Heart (@Open_HeartBMJ) August 29, 2020
#ESCCongress – ESC Position statement: Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease
31 Aug, 2020 | 01:14h | UTC
#ESCCongress – 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease
31 Aug, 2020 | 01:16h | UTCNews Release: Can people with heart disease exercise safely? – European Society of Cardiology
Commentary on Twitter
Finally out. ESC sports cardiology guidelines for exercise in patients with cardiovascular disease.https://t.co/1hLbhfLdIb @s_gati @MichaelPapadak2 @StGeorgesUni @DrAneilMalhotra @DrSarahClarke @SilCastelletti @DrTiberi @DreznerJon @TJ_Yeo @CSHeartResearch #ESCCongress pic.twitter.com/JIrgPLaKQY
— Sanjay Sharma (@SSharmacardio) August 29, 2020
#ESCCongress – 2020 ESC Guidelines for the management of adult congenital heart disease
31 Aug, 2020 | 01:13h | UTCNews Release: What happens when babies with heart defects become adults? – European Society of Cardiology
Commentary on Twitter
2020 ESC Guidelines for management of adult congenital heart diseasehttps://t.co/MPHMJ2KKIc#ESCCongress #ACHD #CardioTwitter #ESCGuidelines @ErinMichos @DrMarthaGulati @ddefariayeh @AmiBhattMD @FredWuMD @anudodejamd pic.twitter.com/4LrrnAAxZ1
— Open Heart (@Open_HeartBMJ) August 29, 2020